CardiologyNowNews.org CardiologyNowNews.org
Font ResizerAa
  • Home
    • About
      • Message from the Editor-in-Chief
      • Mission Statement
      • Editorial Board
  • News
  • Topics
    • Acute Coronary Syndrome
    • Arrhythmia and Electrophysiology
    • Cardiovascular Imaging
    • Cardiovascular Intervention
    • Cardiovascular Prevention
    • Cerebrovascular Disease
    • Heart Failure
    • Peripheral Vascular Disease
    • Structural Heart Disease
    • Valvular Heart Disease
  • Educational Resources
    • WikiDoc
    • BAIM Grand Rounds
    • Clinical Trial Results
  • ACC
    • ACC 2017
    • ACC 2018
    • ACC 2019
    • ACC 2020
    • ACC 2021
    • ACC 2022
    • ACC 2023
    • ACC 2024
    • ACC 2025
    • ACC 2026
  • AHA
    • AHA 2017
    • AHA 2019
    • AHA 2021
    • AHA 2022
    • AHA 2023
    • AHA 2024
    • AHA 2025
    • AHA 2026
  • ESC
    • ESC 2017
    • ESC 2018
    • ESC 2019
    • ESC 2021
    • ESC 2022
    • ESC 2023
    • ESC 2024
    • ESC 2025
  • SCAI
    • SCAI 2017
    • SCAI 2018
  • Videos
CardiologyNowNews.org CardiologyNowNews.org
Font ResizerAa
Search
  • Home
    • About
  • News
  • Topics
    • Acute Coronary Syndrome
    • Arrhythmia and Electrophysiology
    • Cardiovascular Imaging
    • Cardiovascular Intervention
    • Cardiovascular Prevention
    • Cerebrovascular Disease
    • Heart Failure
    • Peripheral Vascular Disease
    • Structural Heart Disease
    • Valvular Heart Disease
  • Educational Resources
    • WikiDoc
    • BAIM Grand Rounds
    • Clinical Trial Results
  • ACC
    • ACC 2017
    • ACC 2018
    • ACC 2019
    • ACC 2020
    • ACC 2021
    • ACC 2022
    • ACC 2023
    • ACC 2024
    • ACC 2025
    • ACC 2026
  • AHA
    • AHA 2017
    • AHA 2019
    • AHA 2021
    • AHA 2022
    • AHA 2023
    • AHA 2024
    • AHA 2025
    • AHA 2026
  • ESC
    • ESC 2017
    • ESC 2018
    • ESC 2019
    • ESC 2021
    • ESC 2022
    • ESC 2023
    • ESC 2024
    • ESC 2025
  • SCAI
    • SCAI 2017
    • SCAI 2018
  • Videos
Follow US
AHA 2026News

ISCHEMIA-EXTEND: Initial Invasive Management Does Not Improve Long-Term Survival in High-Risk Chronic Coronary Disease

Anum Ijaz
Share
5 Min Read
  • Whether routine invasive management added to guideline-directed medical therapy (GDMT) improves long-term survival in patients with chronic coronary disease and moderate or severe ischemia remains uncertain.
  • This long-term follow-up of the ISCHEMIA randomized trial tracked all 5,179 participants for a median of 9 years (maximum 13.4 years).
  • All-cause mortality did not differ significantly between the initial invasive and initial conservative strategies, suggesting that the choice between them can rest on symptoms and patient preference rather than an expected survival gain.

Randomized trials of elective revascularization added to medical therapy in stable coronary disease have not demonstrated reductions in death or myocardial infarction (MI). The long-term follow-up of COURAGE (1,211 patients, up to 15 years) found no survival benefit with percutaneous coronary intervention plus medical therapy compared with medical therapy alone.

The ISCHEMIA trial randomized patients with moderate or severe ischemia to an initial invasive strategy of cardiac catheterization and, when feasible, revascularization plus guideline-directed medical therapy (GDMT) or an initial conservative strategy (GDMT alone, with invasive care for treatment failure). Over a median of 3.2 years, the invasive strategy did not reduce major cardiovascular (CV) events but lowered the risk of spontaneous MI improved angina symptoms, with a cost of more periprocedural MI. At a median of 5.7 years, an interim analysis showed similar all-cause mortality, with lower CV but higher non-CV mortality in the invasive group. Whether fewer spontaneous MIs translate into long-term survival remains uncertain.

On November 7th, 2026, the final long-term results of the “International Study of Comparative Health Effectiveness with Medical and Invasive Approaches” trial (ISCHEMIA-EXTEND; NCT04894877) were presented at the American Heart Association Scientific Sessions in Chicago, IL, by Dr. Judith S. Hochman. The purpose of this analysis was to compare long-term all-cause, CV and non-CV mortality between the initial invasive and initial conservative strategies in stable patients with moderate or severe coronary ischemia. The results were simultaneously published in the Journal of the American Medical Association.

ISCHEMIA-EXTEND followed patients from the ISCHEMIA randomized trial conducted at 320 sites in 37 countries. Patients had chronic coronary disease, moderate or severe ischemia and no significant left main coronary artery disease (≥50% stenosis), recent acute coronary syndrome, or ejection fraction below 35%. A total of 5,179 patients were randomized 1:1 to the invasive (n=2,588) or conservative (n=2,591) strategy. Survival was tracked through December 2025. Primary outcomes were all-cause mortality, CV and non-CV mortality.

Patients had a median age of 64 years, 77% were male and 42% had diabetes; groups were balanced. Median follow-up was 9 years (maximum 13.4 years). By 11 years, the risk of death did not differ significantly between the invasive and conservative strategy groups (25.8% vs 26.9%; adjusted HR 0.97 [95% CI, 0.86–1.09]). The average time patients lived over 11 years differed by 14 days (95% CI, −41 to 70). A Bayesian analysis showed that a meaningful survival benefit with the invasive strategy was unlikely at 9 years (18% probability of a >1-percentage-point reduction in death). CV mortality was numerically lower with the invasive strategy (15.8% vs 17.1%; adjusted HR 0.88 [95% CI, 0.75–1.02]), whereas non-CV mortality was numerically higher (9.1% vs 8.1%; adjusted HR 1.18 [95% CI, 0.96–1.45]); neither difference was statistically significant. All-cause mortality results were consistent across subgroups.

Limitations of this study include the absence of follow-up on nonfatal events, medications, revascularization procedures and quality of life after a median of 3.2 years. In addition, causes of death were not adjudicated during the extended phase.

The authors concluded that, over a median of 9 years, an initial invasive strategy did not significantly change all-cause mortality compared with a conservative strategy; a likely small reduction in CV mortality was offset by slightly higher non-CV mortality. These findings can inform decisions about adding invasive management to GDMT. Ongoing work aims to develop individualized risk scores from these long-term mortality data.

TAGGED:AHA 2026FeaturedNews
Share This Article
Copy Link Print
CardiologyNowNews.org CardiologyNowNews.org
Copyright - CardiologyNowNews
  • Contact Us
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?